StockWatch
·
Biotechnology: Pharmaceutical Preparations
Clinical TrialJul 7, 2026, 11:19 AM

Theriva Biologics VIRAGE2 Clinical Trial for Pancreatic Cancer Approved

AI Summary

Theriva Biologics announced that the Spanish Agency of Medicines and Medical Devices (AEMPS) has authorized the initiation of the VIRAGE2 clinical trial. This Phase IIa study is designed to optimize the dosing regimen of VCN-01 in combination with standard chemotherapy for patients with newly diagnosed metastatic pancreatic cancer. The trial builds upon positive clinical data from the previous VIRAGE study and feedback from the EMA and FDA, which suggested the potential for improved outcomes with more frequent VCN-01 administration.

Key Highlights

  • AEMPS authorized Theriva Biologics to start VIRAGE2 clinical trial.
  • VIRAGE2 is a Phase IIa study for newly diagnosed metastatic pancreatic cancer.
  • It evaluates increased dosing frequency of VCN-01 with gemcitabine/nab-paclitaxel.
  • Trial aims to determine optimal VCN-01 dosing for a future pivotal Phase III study.
  • Based on positive Phase IIb VIRAGE trial results, showing improved survival with VCN-01.
  • EMA and FDA recognized potential benefits of more frequent VCN-01 administration.
  • VIRAGE2 will assess tolerability of at least three VCN-01 doses, two months apart.